Spyre Therapeutics (SYRE) falls 14.31% after-hours following SKYWAY trial data and strategic pivot

ByAinvest Wire

Tuesday, Aug 25, 2026 4:21 pm ET1min read

Spyre Therapeutics (SYRE) shares fell 14.31% in after-hours trading following the release of topline results from the rheumatoid arthritis sub-study of its SKYWAY Phase 2 trial for SPY072. While the drug showed statistical significance over placebo, the company announced it will not prioritize monotherapy development in RA because the magnitude of effect did not meet internal thresholds, shifting focus to combination strategies and broader TL1A potential.

Stay ahead of the market.

Get curated U.S. market news, insights and key dates delivered to your inbox.

Comments

﻿

No comments yet

AInvest
PRO

Editorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process. While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context. Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Spyre Therapeutics (SYRE) falls 14.31% after-hours following SKYWAY trial data and strategic pivot

Stay ahead of the market.

Comments

AInvestPRO

AInvest

AInvest
PRO